NPCE
$13.00-0.13 (-0.99%)
NeuroPace, Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant fo...
Recent News
How The NeuroPace (NPCE) Story Is Shifting As Analysts Refresh Valuation Assumptions
NeuroPace is back on investor radar as analysts update their models and lift the fair value price target from US$19.43 to about US$19.88. Some see this roughly US$0.45 move as better aligned with revised expectations around the company’s growth trajectory. Others point out that it may leave less room for error if forecasts do not play out as modeled. As you read on, you will see how these shifts shape the evolving narrative and what to watch next in the story. Analyst Price Targets don't...
Key Catalysts That Will Likely Drive Prospects for NPCE Stock in 2026
NPCE heads into 2026 with 20%+ RNS growth targets, higher Medicare reimbursement and a cleaner revenue mix as the DIXI distribution business rolls off.
NPCE RNS System Explained: Growth Drivers and Setup for 2026
NPCE enters 2026 with rising RNS adoption, stronger margins and Medicare payment hikes that could boost hospital economics for replacement procedures.
NeuroPace's Seizure ID and New Indication Could Expand RNS Demand
NPCE's Seizure ID AI tool and potential idiopathic generalized epilepsy approval could expand RNS adoption as NeuroPace pushes software-driven care in 2026.
Why NeuroPace Stock Was Inching Higher on Wednesday
The company finished 2025 with a convincing pair of earnings beats.